Petco Health and Wellness Company Valuation
Is WOOF * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of WOOF * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WOOF * (MX$31) is trading above our estimate of fair value (MX$20.57)
Significantly Below Fair Value: WOOF * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WOOF *?
Other financial metrics that can be useful for relative valuation.
What is WOOF *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$779.88m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.6x |
Enterprise Value/EBITDA | 18.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does WOOF *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.6x | ||
GIGANTE * Grupo Gigante S. A. B. de C. V | 0.9x | n/a | Mex$31.8b |
GPH 1 Grupo Palacio de Hierro. de | 0.4x | n/a | Mex$16.6b |
MATAS Matas | 0.8x | 15.3% | kr.4.5b |
HZO MarineMax | 0.2x | 4.0% | US$588.8m |
WOOF * Petco Health and Wellness Company | 0.1x | 0.9% | Mex$779.9m |
Price-To-Sales vs Peers: WOOF * is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does WOOF *'s PE Ratio compare vs other companies in the South American Specialty Retail Industry?
Price-To-Sales vs Industry: WOOF * is good value based on its Price-To-Sales Ratio (0.1x) compared to the Global Specialty Retail industry average (0.5x).
Price to Sales Ratio vs Fair Ratio
What is WOOF *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate WOOF *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$31.00 | Mex$47.87 +54.4% | 37.9% | Mex$83.31 | Mex$16.66 | n/a | 13 |
May ’25 | n/a | Mex$49.62 0% | 45.4% | Mex$99.37 | Mex$16.56 | n/a | 14 |
Apr ’25 | n/a | Mex$54.17 0% | 42.6% | Mex$100.12 | Mex$16.69 | n/a | 14 |
Mar ’25 | Mex$43.00 | Mex$63.91 +48.6% | 32.3% | Mex$102.56 | Mex$17.09 | n/a | 14 |
Feb ’25 | n/a | Mex$64.46 0% | 32.3% | Mex$103.42 | Mex$17.24 | n/a | 14 |
Jan ’25 | n/a | Mex$67.58 0% | 24.3% | Mex$103.01 | Mex$47.21 | n/a | 14 |
Dec ’24 | Mex$52.00 | Mex$72.10 +38.6% | 30.6% | Mex$120.38 | Mex$47.29 | n/a | 13 |
Nov ’24 | Mex$60.00 | Mex$115.81 +93.0% | 25.3% | Mex$180.30 | Mex$72.12 | n/a | 13 |
Oct ’24 | Mex$66.00 | Mex$113.30 +71.7% | 22.4% | Mex$171.26 | Mex$68.50 | n/a | 13 |
Sep ’24 | Mex$89.50 | Mex$110.84 +23.8% | 22.4% | Mex$167.55 | Mex$67.02 | n/a | 13 |
Aug ’24 | Mex$135.00 | Mex$169.15 +25.3% | 17.3% | Mex$205.34 | Mex$102.67 | n/a | 13 |
Jul ’24 | Mex$153.50 | Mex$169.15 +10.2% | 17.3% | Mex$205.34 | Mex$102.67 | n/a | 13 |
Jun ’24 | Mex$143.70 | Mex$173.10 +20.5% | 17.0% | Mex$211.50 | Mex$105.75 | n/a | 14 |
May ’24 | Mex$175.02 | Mex$192.00 +9.7% | 19.9% | Mex$269.70 | Mex$125.86 | n/a | 14 |
Apr ’24 | Mex$163.00 | Mex$202.59 +24.3% | 28.3% | Mex$364.53 | Mex$127.58 | n/a | 13 |
Mar ’24 | Mex$196.00 | Mex$267.37 +36.4% | 20.7% | Mex$377.80 | Mex$170.01 | Mex$43.00 | 13 |
Feb ’24 | Mex$223.60 | Mex$264.21 +18.2% | 20.9% | Mex$375.38 | Mex$168.92 | n/a | 13 |
Jan ’24 | n/a | Mex$286.42 0% | 20.4% | Mex$396.11 | Mex$178.25 | n/a | 13 |
Dec ’23 | Mex$192.88 | Mex$284.39 +47.4% | 23.2% | Mex$421.43 | Mex$172.40 | Mex$52.00 | 13 |
Nov ’23 | n/a | Mex$342.82 0% | 27.5% | Mex$591.60 | Mex$197.20 | Mex$60.00 | 13 |
Oct ’23 | n/a | Mex$379.73 0% | 21.7% | Mex$611.96 | Mex$244.78 | Mex$66.00 | 13 |
Sep ’23 | n/a | Mex$380.08 0% | 22.5% | Mex$597.51 | Mex$239.01 | Mex$89.50 | 12 |
Aug ’23 | Mex$282.00 | Mex$426.15 +51.1% | 21.9% | Mex$611.22 | Mex$264.86 | Mex$135.00 | 12 |
Jul ’23 | Mex$303.50 | Mex$436.90 +44.0% | 20.0% | Mex$598.04 | Mex$259.15 | Mex$153.50 | 12 |
Jun ’23 | Mex$315.00 | Mex$437.91 +39.0% | 19.9% | Mex$594.90 | Mex$257.79 | Mex$143.70 | 12 |
May ’23 | Mex$440.00 | Mex$505.62 +14.9% | 16.8% | Mex$617.99 | Mex$318.96 | Mex$175.02 | 11 |
Analyst Forecast: Target price is lower than the current share price.